This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Evolent Health, Inc.
11/5/2026
Good morning and welcome to the Evelyn Earnings Conference Call for the third quarter ended September 30th, 2026. As a reminder, this conference call is being recorded. Your hosts for the call today from Evelyn are Seth Blackley, Chief Executive Officer, and Mario Ramos, Chief Financial Officer. An audio playback of the conference call will be archived and available later this evening and for 90 days after this call via the webcast on the company's website in the section titled Investor Relations. This conference call will contain forward-looking statements under the US federal laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. A description of some of the risks and uncertainties can be found in the company's reports that are filed with the Securities and Exchange Commission, including cautionary statements included in our current and periodic filings. For additional information on the company's results and outlook, please refer to our third quarter press release issued earlier today. Finally, as a reminder, Reconciliations of non-GAAP measures discussed during today's call to the most direct comparable GAAP measures are available in the summary presentation available in the Investor Relations section of our website or in the company's press release issued today and posted on the Investor Relations website ir.evalent.com and the Form 8-K filed by the company with the SEC earlier today. In addition to reconciliations, We provide details on the numbers and operating metrics for the quarter in both our press release and supplemental investor presentation. I will now turn the call over to Evelyn's CEO, Seth Blackley. You may now begin.
Good morning and thank you for joining us. Today we reported the third quarter results that we believe reflect strong continued progress against the priorities we laid out at the beginning of the year. We grew our performance suite business. improved our care margins and stayed disciplined on operating expenses, all while continuing to innovate at the core of our business. For the quarter, Evelyn reported total revenue of $725 million, up 11% versus Q2, and adjusted EBITDA of $34 million, up approximately 22% sequentially. Our medical expense ratio, or MER, was 93% compared with 95% in the second quarter. The improvement reflects favorable in-year claims development and contractual adjustments. Mario will provide more details on those drivers in a few moments. Based on our results through the first nine months and our current view of the fourth quarter, we are reiterating our full-year revenue guidance of $2.6 billion to $2.7 billion and raising our adjusted EBITDA guidance to $130 million to $135 million. Before turning it over to Mario, I want to talk you through four topics. One, the strength of our customer relationships and the related growth. Two, updates from our 2026 performance suite launches. Three, how we are both broadening our product footprint and accelerating our AI innovation. And fourth, our balance sheet. Let's start with the initial topic of customer relationships and growth. As we've discussed on previous calls, renewals and expansions are at the heart of our growth story. I'd like to share several proof points of that today. First, we renewed our largest surgical management customer contract for an additional four years. You will recall surgical management is the IPG business we acquired in 2022. We view this as more than a renewal. It's a longstanding partner committing to a multi-year deal, demonstrating that our model work and that they want us at their side managing musculoskeletal and cardiovascular care for the long run. Second, an existing client signed an agreement to expand their oncology offering covering several additional states and approximately 1 million commercial lives with Go Live expected January 1, 2027. This is our first expansion with this client and we believe it demonstrates the trust they've placed in us but also something more strategically important. It's significant to note that this expansion will also include member navigation across all existing and new lives, meaning we're not just growing with the client. We are broadening the footprint by adding our member-facing solution. This is exactly the kind of product breadth expansion that defines our next phase of growth, taking a client under contract with one solution and giving them a reason to trust us with additional solutions. Third, we're expanding our relationship with a national payer in the specialty technology and services product, adding 11 additional states, effective November 1, 2026. These 11 additional states add to our existing footprint of 39, making Evelyn this client's nationwide provider across our full suite of oncology specialties. This client now represents approximately 7 million lives, all of which are managed by Evelyn. Alongside that expansion, we rolled out a new cancer care model in partnership with the American Oncology Network, or AON, that aims to reduce the prior authorization burden for providers designed to improve quality, timeliness, and affordability for patients. This model has been initially rolled out across clinics in eight states, and it's a blueprint for where we believe oncology care is headed, which is less friction, more trust, and better outcomes. Taken together, we believe these wins tell a consistent story. Our customers are not just staying with us, they're asking us to do more for them, which gives us a durable foundation to keep expanding our products and deepening the value we deliver over time. Next, as in quarters past, I want to update you on our 2026 performance suite launches with Ed and Highmark. As of Q3, we are now beginning to see favorable claims run out relative to our initial reserves, contributing to the MER favorability we're seeing this quarter and reflecting our successful implementations. Mario will speak to this in more detail shortly. On Highmark specifically, we continue to make strong progress since our launch in May, and while it's still early in the partnership, we believe we're ahead of plan with all the leading indicators tracking better than budget. Let me now turn to the third update, which is product expansion and innovation. In terms of our broader strategy, our growth trajectory rests on two pillars that I remain excited about. The first one is continuing to push the boundaries of our core specialty offering, especially in oncology, which remains the largest and most important growth driver for our business, and we believe will represent over 70% of Evelyn's 2027 revenue. Health plans are navigating a Specialty in oncology where effective treatment can mean choosing correctly among a wide range and growing range of evidence-based regimens for a single cancer type, which is exactly why we believe the clinical depth we bring matters and why we keep investing in it. As I mentioned earlier, we've expanded the oncology solution as it relates to our member-facing navigation product. In addition, we're embedding our clinical pathways directly into the EMRs of leading oncology groups in our network. We expect both of those innovations to continue to expand over the coming years. Our second pillar is AI, which is relevant for all of our specialties, oncology of course, but even more so in high volume areas like imaging, musculoskeletal care, and cardiovascular care. I want to spend a moment updating you on our progress and share why we believe We are now the market leader in AI for specialty reviews. We have been building our foundation in AI for several years, beginning with our acquisition of Machinify Auth, an AI native utilization management technology in 2024. We have since integrated and scaled that platform into what we now call Auth Intelligence. We took that platform from initial test markets to deployment over the past year, and we believe the initial results are incredibly strong. Let me step back and remind you of the purpose of this AuthIntelligence platform. First, according to medical literature, approximately 20% of care across any given specialty is the wrong or inappropriate care defined as unnecessary, low value, or dangerous to the member. It creates costs and increased premiums and copays for members, and more importantly, may risk their health and safety. At Evelyn, we're focused on identifying which 20% of cases are the wrong or inappropriate care and which 80% represent appropriate care. Our authintelligence platform uses our unique clinical pathways and over 15 years of proprietary data to identify in real time which is the 20 and which is the 80. The result of any false positive or false negative means touching cases with manual review that are in the 80 that could have been auto-authorized at low cost to the AI provider or missing cases that are in the 20 that need more nuanced human intervention. We believe that with auth intelligence in place, we're able to correctly identify both the 80 and the 20, improving the process for patients and providers while maintaining the clinical value and clinical safety for our health plan partners. Because getting this model right requires large amounts of unique data, and because the model will continue to learn in a self-reinforcing loop, we believe this capability provides an important moat for Evelyn in the years to come. Over the last several months, AuthIntelligence has moved well beyond pilot phases, and today, where deployed, AuthIntelligence evaluates approximately half of all our prior authorization volume that previously required manual clinical review, and today, Auth Intelligence is touching approximately 1 million cases per year. And we expect that more than 80% of all manual Auths are approximately 2 million cases to run through our Auth Intelligence platform by the end of 2027. Importantly, at customers and case types where Auth Intelligence is deployed, we have seen auto approval rates improve by as much as 20 percentage points while maintaining clinical value. Said another way, we have seen auto authorization rates jump from 60% to 80% in certain instances. It's important to note that just a 10% improvement in our auto authorization rate translates to a reduction in approximately 600,000 manual touches per year, driving meaningful operating cost savings for Evelyn. When we share some of those savings back with our clients in various forms, We believe our AI platform will be a source of margin expansion and, given the differentiation of our solution, particularly in its ability to drive efficiency while maintaining clinical value, will also be a driver of market share expansion and revenue growth in the time ahead. In January, we'll be hosting a national webinar to update our customers on our AI innovations as well as to discuss an exciting oncology product enhancement. We will be inviting select investors to also attend this product session and will be in touch with you about the event details for those who would like to attend. Finally, on the balance sheet, we have been consistently focused on capital allocation and enhancing financial flexibility. By the end of the year, we are targeting to deploy up to $50 million towards reducing outstanding indebtedness. This reflects our confidence in the business, the earnings trajectory we have delivered this year, the visibility provided by our renewals and performance suite partnerships, and the cash generation we expect as those partnerships mature. We will retain flexibility in the timing and form of that reduction in debt, which will be subject to market conditions and other factors, and guided by what we believe is in the best interest of our shareholders, which is focusing on maintaining strong liquidity operate and invest in the business. Mario will discuss our capital allocation priorities in more detail. To conclude, our third quarter results show continued progress in growing our business, retaining important customer relationships, and improving profitability. We remain focused on delivering our 2026 commitments and building a strong foundation for the year ahead. With that, let me turn it over to Mario.
Our third quarter results reflect continued growth in the performance suite and strong MER performance. Total revenue was 725 million, up approximately 11% versus the second quarter. Adjusted EBITDA was 34.3 million, up approximately 22% sequentially. That sequential earnings improvement is slightly above the midpoint of the 4 million to 7 million increase we outlined on our Q2 2026 call. Turning to revenue by product type, performance suite revenue was $564 million, up approximately 16% quarter over quarter. The increase was primarily due to a full quarter of Highmark revenue and the recognition of contractual adjustments. Specialty technology and services revenue was $73 million, down approximately 7% sequentially, reflecting a Q2 benefit from reversing a credit for an anticipated Q1 membership decline that did not materialize. Administrative services revenue was $48 million, remaining relatively flat sequentially as a one-time favorable implementation credit offset the impact of known client attrition. Cases revenue was approximately $40 million, slightly lower sequentially, reflecting seasonality primarily. Our medical expense ratio for Q3 was 93% compared with 95% in Q2, reflecting an approximately 220 basis points sequential improvement. This improvement was due to favorable in-year claims development that came through earlier than expected. that the in-year favorable development reflects better than expected medical expenses in Q1 following claims run out completion. This is separate and distinct from the prior year development recognized in Q2. As a result, we expect a smaller sequential improvement in MER in Q4 with some of the expected benefit already reflected in Q3 but reiterate our full year MER of approximately 93%. On operating expenses, we remain focused on managing both adjusted cost of revenue and adjusted SG&A. Our staffing costs were relatively flat compared to Q2 2026 in both adjusted cost of revenue and adjusted SG&A. This reflects the efficiencies we continue to work on across our operations as we grow the business. Non-staff expense was slightly higher quarter over quarter, largely due to a one-time vendor rebate realized in the second quarter. We continue to pursue cost improvements while funding the technology investments needed to support the business. We are still expecting adjusted cost of revenue, excluding medical claims, but including medical device costs plus adjusted SG&A of approximately $675 million for the year. Turning to cash and liquidity, we ended the quarter with unrestricted cash of $148 million and net debt of $776 million. In Q3 2026, we generated approximately $26 million in cash flow from operations, and capital expenditures remain consistent at approximately $7 million for the quarter. Improvement in cash flow from operations was largely due to one-time items that impacted Q2 2026. First, the repayment of the pass-through proceeds of approximately $20 million, and second, our final lease termination payment of approximately $6 million. For the full year, we continue to expect cash flow from operations of 10 million to 20 million after approximately 60 million of annual cash interest expense. Our operating cash flow forecast is subject to the timing of reconciliation payments we expect to make in late December. We now expect 26 million to 28 million in capital expenditures for the year. Turning to our full year outlook, we are reiterating revenue guidance of $2.6 billion to $2.7 billion and raising our adjusted EBITDA guidance to $130 million to $135 million from $120 million to $135 million previously. For the fourth quarter, we now expect a sequential increase in adjusted EBITDA of approximately $11 million to $16 million, above the $7 million to $15 million step-up we outlined last quarter due to continued MER upside. Looking ahead to 2027, our focus remains on translating the scale of our performance suite business into stronger earnings and cash generation. Let me frame the principal drivers as we see them today. We expect three key tailwinds. First, contract maturation, including a full year of the partnerships launched in 2026, and continued margin improvement as Aetna and Highmark mature. Second, incremental membership growth from new and expanded partnerships. And third, Significant cost reductions driven in part by our AI initiatives and the enterprise-wide cost review we launched earlier this year. Those tailwinds will be partially offset by three headwinds. First, membership attrition, primarily for Medicaid work requirements and, to a lesser extent, some planned client attrition in administrative services. Scope adjustments due to client renewals and contract extensions. And third, continue targeted high return investments such as AI to support growth and efficiency, which carry near term costs. As I just mentioned, our AI program is an important part of these investments. We expect AI related capital expenditures to be higher in 2027 than in 2026. We expect these initiatives to begin generating returns in late 2027, which will be primarily in the form of cost reductions. We then expect additional returns in 2028 and beyond from lower operating costs and, more importantly, from new product launches. The combination of improved MER performance and cost reductions from AI in the second half of 2027 continues to give us a high degree of confidence in the outlook we provided on our Q2 2026 call that the midpoint of 2027 adjusted EBITDA guidance will be $150 million or higher. On revenue, we continue to expect strong growth in 2027 led by performance suite. The ultimate rate of growth will depend on several factors that are still developing. including the timing of new launches, membership trends in Medicaid and the exchanges, and the outcome of scope adjustments due to contract extensions. We will provide our detailed 2027 guidance including a specific revenue range with our fourth quarter results in February. We will continue to be disciplined about the business we add and we are prioritizing margin and cash generation over revenue growth. Finally, let me address our capital structure. As we discussed last quarter, strengthening the balance sheet is a priority, and we are advancing that work through a combination of earnings growth, improved cash flow conversion, disciplined capital allocation, and the evaluation of capital markets and strategic alternatives. With adjusted EBITDA performance continuing to improve, We will begin taking steps towards deleveraging and refinancing our debt. As Seth mentioned, by the end of the year, we are targeting to deploy up to $50 million towards reducing outstanding indebtedness. This reflects our confidence in the business, the earnings trajectory we have delivered this year, the visibility provided by our renewals and performance suite partnerships, and the cash generation we expect as those partnerships mature. Our objective is straightforward. Reduce debt and improve financial flexibility while preserving our ability to execute the operating plan. We will provide updates as appropriate as this work progresses. This is part of the broader effort we described last quarter to improve our leverage and maturity profile over the next 12 to 24 months. We remain focused on both sides of that equation, growing earnings and managing the capital structure. To wrap up, we delivered another quarter of sequential revenue and adjusted EBITDA growth. We have important customer relationships in place and a clear set of operating and balance sheet priorities. We remain focused on delivering our commitments, improving cash generation, and creating long-term value for our clients and shareholders. With that, operator, please open the call for questions.
You're reading a preview of the EVH Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing